Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:41:25.556Z.
Calculation as of: 2026-10-06T14:41:25.556Z.
Quote observation: 2026-10-06T14:40:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4980e4284b6230c79d3dcd5f09fe919c7c05eb80d65ab6e095ba480293e97312
PEG RATIO
N/A
Canton Strategic Holdings Inc
Market Cap
$178.54M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $178.54M | N/A |
| Journey Medical Corporation (DERM)vs › | $180.32M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.60M | N/A |
| MediWound Ltd. (MDWD)vs › | $171.77M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $170.72M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $170.03M | N/A |
| Nkarta, Inc. (NKTX)vs › | $169.48M | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.50M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $191.14M | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $164.54M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
